RxDoctor Payments Data

Howard Boey, MD

Otolaryngology · New Haven, CTNPI 1306868229

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (51.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Optinose US, Inc. at 57.9% of the total. 2025 is the largest year on record at $7,063, 2.6 times the $2,675 reported in 2019. Among otolaryngology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,456in general payments, 2019–2025

Across 220 payments — averaging $88.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$11K
  • Intersect ENT, Inc.$3K
  • Aerin Medical Inc.$2K
  • GSK$931
  • Sanofi$636
  • Medical Device Business Services, Inc.$316
  • plus $1K from 12 others

What the payments were for

  • Speaking & faculty fees$10,00051%
  • Travel & lodging$2,47513%
  • Food & beverage$6,98136%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,456 in reported general payments places this provider in the 95th percentile of 119 otolaryngology providers in Connecticut.

See all otolaryngology providers in Connecticut

Medicare billing

Part B allowed, 2024
$160,752
Medicare patients
532
Services billed
1,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate24$14,382
Cevimeline Hcl18$5,337
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth32$3,464
Ipratropium Bromide127$2,542
Azelastine Hcl65$1,481
Hydrocortisone-Acetic AcidHydrocortisone/Acetic Acid12$1,317
Ofloxacin46$1,004
Fluticasone Propionate64$968
Mometasone Furoate15$695
Nystatin18$691
Cephalexin17$293
Prednisone60$262
Doxycycline Hyclate20$212
Mupirocin19$169
Montelukast Sodium12$140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$11,262$14,38224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 119 otolaryngology providers in Connecticut.

Other otolaryngology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →